Drug Trial Radar · NCT07214870
A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
29
Actual
Start
Oct 8, 2025
Primary completion
May 14, 2027
Study completion May 14, 2027
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Oct 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical study is to find out if NNC4005-0001 is well-tolerated and safe for people who have increased body weight and increased liver fat. Participants will receive either NNC4005-0001, which is the treatment being tested, or a placebo, which is a treatment that contains no active medicine. The study will last for about for about 7 to 8 months.
Conditions
- Fatty Liver Disease
Interventions
NNC4005-001Drug
NNC4005-0001 will be given as a single ascending dose via subcutaneous route
PlaceboDrug
Placebo matched to NNC4005-0001 will be given via subcutaneous route
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Treatment-emergent adverse event (TEAEs)Time frame: From dosing (day 1) until compeletion of end of study (EOS) visit on day 169
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Altasciences Clinical Company, Inc
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.